Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

J. C. von Einem,Volker Heinemann,L. Fischer von Weikersthal,Ursula Vehling-Kaiser,Martina Stauch,Holger Hass,Thomas Decker,Stefan Klein,Swantje Held,Andreas Jung,Thomas Kirchner,Michael Haas,Julian Walter Holch,Marlies Michl,Philipp Aubele,Stefan Boeck,Ch. Schulz,Clemens Giessen,Sebastian Stintzing,Dominik Paul Modest

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

2014

Purpose AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus cetuximab, capecitabine and oxaliplatin. This analysis investigated the impact of primary tumor location on outcome of patients.

Keywords:

Capecitabine
Primary tumor
Cetuximab
KRAS
Colorectal cancer
Oxaliplatin
Irinotecan
Biology
General surgery
Chemotherapy
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations